213 related articles for article (PubMed ID: 33849364)
1. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
2. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy.
Mysliwiec J; Palyga I; Nikolajuk A; Kowalska A; Gorska M
Endokrynol Pol; 2012; 63(2):92-6. PubMed ID: 22538746
[TBL] [Abstract][Full Text] [Related]
4. Increased serum VEGF and b-FGF in Graves' ophthalmopathy.
Ye X; Liu J; Wang Y; Bin L; Wang J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1639-44. PubMed ID: 24867311
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves' orbitopathy: A preliminary study.
Kościuszko M; Popławska-Kita A; Pawłowski P; Lipińska D; Hryniewicka J; Jankowska D; Górska M; Krętowski A; Myśliwiec J
Adv Med Sci; 2021 Sep; 66(2):315-320. PubMed ID: 34256242
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
7. The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy.
Lacka K; Manuszewska E; Korczowska I; Lacki JK
Curr Eye Res; 2007 Mar; 32(3):291-7. PubMed ID: 17453949
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
9. Serum pro- and anti-inflammatory cytokines in patients with Graves' disease with ophthalmopathy during treatment with glucocorticoids.
Myśliwiec J; Kretowski A; Szelachowska M; Mikita A; Kinalska I
Rocz Akad Med Bialymst; 1999; 44():160-9. PubMed ID: 10697431
[TBL] [Abstract][Full Text] [Related]
10. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
12. Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids.
Naselli A; Moretti D; Regalbuto C; Arpi ML; Lo Giudice F; Frasca F; Belfiore A; Le Moli R
Front Endocrinol (Lausanne); 2020; 11():609895. PubMed ID: 33414766
[TBL] [Abstract][Full Text] [Related]
13. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
[TBL] [Abstract][Full Text] [Related]
14. [Serum IL-1 receptor antagonist and IL-1beta in patients with Graves' opthalmopathy].
Xie Q; Li SQ; Aa ZM; Wei SQ; Zhao HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):238-41. PubMed ID: 16608084
[TBL] [Abstract][Full Text] [Related]
15. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
16. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
17. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
[No Abstract] [Full Text] [Related]
18. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
19. Changes in ocular biomechanics after treatment for active Graves' orbitopathy.
Li HX; Zhao XH; Song Y; Mu BK; Pan Y; Zhao H; Wang Y
J Endocrinol Invest; 2021 Mar; 44(3):453-458. PubMed ID: 32507991
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Perez-Moreiras JV; Gomez-Reino JJ; Maneiro JR; Perez-Pampin E; Romo Lopez A; Rodríguez Alvarez FM; Castillo Laguarta JM; Del Estad Cabello A; Gessa Sorroche M; España Gregori E; Sales-Sanz M;
Am J Ophthalmol; 2018 Nov; 195():181-190. PubMed ID: 30081019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
